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Formalin-fixed paraffin-embedded tissue (FFPET) samples are invaluable sources for both 
translational clinical research and molecular in vitro diagnostics. However, accurate detection 
of genetic mutations in FFPET is a major challenge due to artifactual results, due to sample age 
and quality. In a pre-clinical study, we used 315 non-small cell lung cancer (NSCLC) FFPET-
derived DNA (FFPET-DNA) samples to establish sample criteria reflecting the minimum DNA 
quality suitable for PCR by comparing the results of droplet digital PCR-based mutation test 
(ddEGFR test) and qPCR-based EGFR mutation test (cobas®  EGFR test). Using this criteria, 
we conducted a retrospective comparative clinical study of the ddEGFR and cobas EGFR tests 
of 171 NSCLC FFPET-DNA samples. Based on the pre-clinical study, the FFPET-DNA sample 
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criterion was established as internal quality control (iQC) index ≥ 0.5 (iQC copies ≥ 500, using 
3.3 ng [1000 genome equivalents] of FFPET-DNA), indicating that more than half of the input 
DNA was amplifiable. Based on this iQC index, an independent clinical study revealed that 
both tests were significantly concordant (overall percent agreement (OPA) = 92.98%). 
Discordants not detected by the cobas EGFR test were detected using the ddEGFR test, 
indicating that the higher sensitivity of the ddEGFR test is due to its lower limit of detection.  
iQC index is a reliable indicator of the quality of FFPET-DNA and could be used to prevent 
incorrect diagnoses arising from low-quality samples. Compared with the cobas EGFR test, the 
ddEGFR test exhibited superior analytical performance and at least equivalent clinical 
performance. ddEGFR test is expected to serve as an appropriate treatment guidance for 
NSCLC patients. 
 
Running title: ddPCR-based EGFR mutation detection with DNA iQC index  
 
Key words: EGFR, epidermal growth factor receptor; FFPE, Formalin-fixed paraffin 
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1. EGFR mutations in NSCLC 
In light of recent advancements in personalized medicine, nucleic acid-based diagnostics 
will play a pivotal role in implementation of targeted therapies. For example, the activation of 
epidermal growth factor receptor (EGFR) pathways results in the initiation of cancer 
proliferation, metastasis, and angiogenesis. EGFR and its relatives are known to be oncogenic 
drivers in cancers such as lung cancer (1), breast cancer (2), and glioblastoma (3-5).  
Lung cancer, which accounts for one-third of cancer-related deaths worldwide, is divided 
into small cell lung cancer (SCLC; which accounts for 20% of cases) and non-small cell lung 
cancer (NSCLC; which accounts for the other 80%). SCLC is a neural crest tumor that responds 
well to chemotherapy, at least initially; however, it often recurs as treatment-resistant disease. 
NSCLC, thought to be derived from lung epithelial cells, includes various subtypes: 
adenocarcinoma, bronchioloalveolar carcinoma, squamous cell carcinoma, and anaplastic and 
large cell carcinoma. Most patients with advanced NSCLC have a very high probability of 
metastasis and, if not treated, the mean survival time and 1 year survival rate is at 4–5 months 
less than 10% respectively (6). Combination cytotoxic chemotherapy increases the survival 
rate only slightly and causes serious non-specific toxicity to the patient (7). However, the 
problem of chemotherapy has been raised in the appearance of molecular targeted therapeutic 
drugs at NSCLC, and small molecule inhibitor of EGFR kinase for treatment of NSCLC was 
approved in 2005 (8). 
Inhibiting EGFR kinase activity using tyrosine kinase inhibitors (TKIs) such as erlotinib and 
gefitinib slows disease progression in patients with NSCLC (9-11). EGFR kinase domain 
mutations occur in four exons encoding part of the tyrosine kinase domain of the enzyme and 
are clustered around the ATP-binding pocket (12). Deletions in EGFR exon 19 and the point 
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mutation L858R constitute about 90% of all EGFR-activating mutations in NSCLC. These 
mutations correlate with a better TKI treatment response rate and with significant increases in 
progression free survival (PFS) (13-18) (Fig. 1 and Table. 1). Some reports suggest that EGFR-
activating mutations may be a prognostic factor for EGFR-TKI efficacy. 
Despite EGFR-TKIs such as erlotinib or gefitinib being used as a standard treatment for 
NSCLC patients harboring EGFR mutations (19), the median PFS still does not exceed 10 
months (20). This is because of the secondary point mutation T790M, which is associated with 
acquired resistance to EGFR-TKIs and is found in up to 50% of post-TKI tumor samples (21-
24). T790M increases receptor binding affinity for ATP, thereby reducing drug activity. Recent 
evidence suggests that the T790M mutation is present in tumor cells at low frequency during 
development of NSCLC, but there is evidence that tumor cells harboring this mutation might 
be enriched during treatment with EGFR-TKIs (25, 26) (Fig. 2). Also, pre-existing EGFR 
T790M mutations are associated with poor clinical outcome after EGFR-TKI therapy for 
NSCLC (27, 28).  
Therefore, new EGFR-TKIs that bind specifically to T790M-mutated receptors have been 
developed and used to treat patients with acquired resistance (29-31). Osimertinib (AZD9291), 
rociletinib (CO-1686), olmutinib (HM61713), and others (Nazartinib, Naquotinib) are 
undergoing clinical trials, and osimertinib (TAGRISSO™) has been approved by the U.S, FDA 
as a treatment for T790M-positive NSCLC (32) (Table.2). Although exciting data and response 
rates have been registered in patients treated with third generation EGFR-TKIs, acquired 
resistance still occurs after about 10 months (29, 30). C797S is another acquired EGFR 
mutation that inhibits the activity of EGFR-TKIs. The first evidence of C797S isolated from 
NSCLC patients was reported by Thress et al (33). The authors analyzed plasma samples from 
19 patients with acquired resistance to osimertinib and identified C797S in six. The C797S 
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mutation appears to be an ideal target for overcoming acquired resistance to third generation 
inhibitors. Thus, accurate detection of EGFR mutations is critical for individualized treatment 







Figure 1. EGFR-TKI sensitizing mutations of EGFR in NSCLC. Exons 18–21 in the 
tyrosine kinase region, in which the relevant mutations are located, are expanded (cyan bars). 
A detailed list of EGFR mutations associated with sensitivity (magenta boxes) or resistance 
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IPASS 71.2 47.3  9.5 6.3  21.6 21.9  (34, 35) 
NEJ002 73.7 30.7  10.8 5.4  30.5 23.6  (17) 
WJTOG3405 62.1 32.2  9.2 6.3  30.9 not reached  (36) 
Erlotinib 
OPTIMAL 83 36  13.1 4.6  22.6 28.8  (37) 
EURTAC 58 15  9.7 5.2  19.3 19.5  (20) 
Afatinib 
LUX-Lung 3 56 23  11.1 6.9  not reported not reported  (38) 
LUX-Lung 6 66.9 23  11 5.6  22.1 22.2  (39) 








Figure 2. Hypothesis explaining T790M mutation-related resistance to EGFR-TKIs 
(gefitinib or erlotinib). Treatment with EGFR-TKIs may result in selection of T790M mutant 
cells. Thus, even if a small number of T790M-positive tumor cells are present at the beginning 















T790M+ T790M-   T790M+ T790M-   T790M+ T790M-   
Osimertinib 
[AZD9291] 
AURA 3 71 31  10.1 4.4  not reported not reported Approved  (40) 
Rociletinib 
[CO-1686] 
NCT01526928 59 29  13.1 5.6  not reported not reported Stopped  (30) 
Olmutinib †  
[HM61713] 


















† Olmutinib has been approved by the Korea Ministry of Food and Drug Safety (MFDS). 
 




2. Companion diagnostics (CDx) 
It is increasingly common for clinicians to analyze molecular characteristics of tumors 
prior to choosing the most appropriate treatment. When used alongside clinically validated and 
accurate companion diagnostics, the therapeutic effect of EGFR-TKI can be maximized. 
In July 2011, the U.S. FDA announced guidelines on the use of companion diagnostics as 
an important tool for guiding the selection and use of appropriate therapies (In vitro companion 
diagnostics devices – guidance for industry and FDA staff, US FDA, 2014). According to this 
definition, CDx analysis is an in vitro diagnostic device that provides essential information for 
the safe and effective use of therapeutic drugs. The FDA also specifies three areas in which a 
CDx assay is required: [i] to identify patients most likely to benefit from a specific therapeutic 
product; [b] to identify patients who may suffer serious side effects as a result of treatment with 
a specific therapeutic product; [c] to monitor treatment responses and adjust the regimen (e.g., 
drug dosage, treatment time) to increase safety and efficacy. The aim of companion diagnostics 
is to thoroughly understand the molecular pathology and mechanism of action of a drug so that 
the properties of a particular molecule are suited to the required treatment outcome. 
A previous report highlights the importance of companion diagnostics comprising 
trastuzumab (Herceptin® , Roche/Genentech) and immunohistochemical (IHC) analysis of 
HER2-positive advanced breast cancer (44). In 1998, the FDA approved trastuzumab and IHC 
for analysis of HER2 overexpression (HercepTest™, Dako); since then, several new targeted 
anticancer agents have been approved and introduced into the clinic. If an appropriate drug and 
dose are to be tailored to suit a particular individual, robust and accurate analysis methods that 
have a short turnaround time are needed. Important factors include standardization of analytical 
methods, validation of reagents and methods, qualified laboratory experience, and involvement 
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of pathologists. However, recent quality assurance studies conducted to confirm the mutation 
status of a standard panel of tumors indicate that, despite using the same or similar methods, 
laboratories may obtain different results (45, 46). Not only differences in methods, but also 
differences in the characteristics of the sample tested and environmental factors at each test 
site, can affect the result; therefore, it is imperative that all procedures are standardized. 
Many techniques were developed instead of direct sequencing for EGFR mutation 
analysis. This is because direct sequencing has low sensitivity, is complex and time consuming, 
and is very difficult to standardize (47). Therefore, new techniques have been developed to 
detect known and de novo mutations, albeit with varying sensitivity (48). The Roche Cobas®  
EGFR Mutation Test (Roche diagnostics, Basel, Switzerland) detects 42 mutations in EGFR 
exons 18, 19, 20, and 21. In parallel with approval of osimertinib as a second-line treatment for 
patients harboring the T790M mutation, the Cobas EGFR test has been approved by the U.S. 
FDA. In particular, the assay overcomes the limitation of requiring tumor tissues because 
EGFR mutation status is assessed in a non-invasive manner. The safety and effectiveness of 
the Cobas EGFR test was confirmed by retrospective clinical validation studies using 
specimens from NSCLC patients screened in the EURTAC trial (49) and establishment through 
AURA 3 clinical trial using matched plasma to the tissues (40). This test allows for EGFR 
mutation screening in a single reaction with a 1-day turnaround time, and has greater sensitivity 
and specificity than Sanger sequencing. 
In July 2013, the Scorpion Amplified Refractory Mutation System (ARMS) therascreen®  
EGFR Rotor-Gene®  Q PCR kit (therascreen EGFR test; QIAGEN, Hilden, Germany) was 
approved by the U.S. FDA for use as a companion diagnostic for afatinib. A recent study 
reported a high concordance rate between the therascreen EGFR test and the Cobas EGFR test 
(50). However, the Cobas EGFR test has some advantages. For example, the time from 
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obtaining a tumor sample to obtaining a result is shorter, meaning that treatment can begin 
more quickly. In addition, Cobas EGFR test requires a very small amount of DNA to detect the 





Roche Cobas®  EGFR mutation 
test 
QIAGEN therascreen EGFR 
RGQ mutation test 
Platform Real time-PCR Real time-PCR 
Instrument Cobas z 480 Analyzer Rotor-Gene®  Q MDx 
IVD, CDx 
Label 
EGFR_CDx (US-FDA approved) EGFR_CDx (US-FDA approved) 
Drug  
TARCEVA®  (Erlotinib), 
TAGRISSO™  (Osimertinib) 
GILOTRIF®  (Afatinib) 
Intended 
use 
The test is intended to be used as 
an aid in selecting patients with 
NSCLC for whom TARCEVA®  
(erlotinib) and TAGRISSO™  
(Osimertinib), an EGFR tyrosine 
kinase inhibitor (TKI), is indicated. 
The test is intended to be used to 
select patients with NSCLC for 
whom GILOTRIF™ (afatinib), an 
EGFR tyrosine kinase inhibitor 
(TKI), is indicated. 
Mutation 
coverage 
G719X, E19del, T790M, S768I, 
E20Ins, L858R, L861Q 
E19del, L858R(CDx) + L681Q, 
G719X, S768I, exon 20 insertions, 
and T790M  
 Total: 42 mutation sites Total: 15 mutation sites  
Detection 
method  
Allele-specific primer ARMS and Scorpions 
Input DNA 
FFPE : 50 ng / well FFPE : 80 ng / well 
cfDNA : 25 μl / well  - 
Reaction 
(well) no.  
3 8 
Sensitivity 
FFPE : 5% FFPE : 1% 
cfDNA : <100 copies /ml - 
Application FFPE,  cfDNA FFPE 
Running 
time 
~2 h ~3 h 
 




3. DNA damage in FFPETs 
Formalin-fixed, paraffin-embedded tissue (FFPET) is the most widely available material for 
molecular diagnostics and clinical research (51). Fixing cancer tissues in buffered formalin is 
a standard procedure because it preserves tissue and cellular morphology prior to examination 
by anatomical pathologists. The routine formalin-fixation process stabilizes proteins by cross-
linking, thereby maintaining tissues in an excellent condition for histopathological analysis 
(52). FFPET samples can be stored at room temperature, which means that damage caused by 
freezing can be avoided. However, the FFPET fixation procedure and long-term storage at 
room temperature causes several kinds of damage to nucleic acids, creating challenges to 







Figure 3. Various DNA damage in FFPET. The FFPETs have some advantages, such as easier 




3.1 DNA fragmentation 
Increased storage time and low pH lead to fragmentation of DNA in FFPET. PCR performed 
by using fresh FFPET is usually much more successful than that of using FFPET that has been 
stored for some time, indicating that DNA fragmentation occurs continuously during storage 
(54-57). Fragmented DNAs reduce the success of PCR amplification since this depends on the 
size of the amplicon (58). Also, DNA fragmentation correlates inversely with sequence 
coverage and can lead to substantial changes in the amount of amplifiable template, which is 
in turn related to the presence of sequencing artifacts (57, 59). 
 
3.2 Hydrolytic deamination 
Hydrolytic deamination of cytosine residues yields uracil lesions, which are a major source 
of artifacts when sequencing FFPET-DNA (60-62). In the human genome, cytosine 
deamination occurs at an estimated rate of 60–500 events/day (63). Among the sequence 
artifacts detected in FFPET DNA, C:G > T:A transitions are the most common type of single 
nucleotide variant (Fig. 4) (64). Recent comparisons of sequencing data generated from fresh-
frozen and FFPET demonstrated that the majority of false-positive and -negative mutation calls 
were made for FFPET samples, particularly in low quality samples (64, 65). Recently, Do, H 
et al. have examined sequence artifacts in FFPET DNA samples, highlighting the importance 
of DNA lesions (66). For example, the T790M mutation in EGFR is a predictor of TKI 
resistance in NSCLC patients (67); therefore, an FFPET artefact causing a false-positive result 





Figure 4. Hydrolytic deamination of cytosine residues. Deamination of cytosine residues 
results in non-reproducible artifacts. EGFR G719S and T790M are the most common false-




3.3 Formaldehyde-induced abasic site 
Formaldehyde induced abasic sites are generated by depurination. When it reacts with 
oxygen in the atmosphere, formaldehyde is readily oxidized to formic acid, which reduces the 
pH of a formalin solution. Formalin solutions are therefore buffered to maintain a neutral pH. 
In DNA, the N-glycosidic bonds between a purine base and its deoxyribose moiety are most 
susceptible to hydrolysis at low pH (70); thus, fixation of tissues in unbuffered formalin will 
lead to a marked reduction in the amount of amplifiable DNA template (71). Abasic sites also 
cause problems with respect to sequence analysis. Chemical alterations in DNA block the 
passage of DNA polymerase, resulting in sequence artifacts (72, 73). 
 
3.4 Formaldehyde-induced cross-link 
Cross-linking reduces the stability of double stranded DNA, which in turn affects the amount 
of FFPET DNA that can be amplified by PCR (74). Formaldehyde, the main component of 
formalin, induces crosslinks between proteins and between proteins and DNA; it also induces 
DNA-formaldehyde adducts and inter-strand DNA crosslinks, all of which have a primary 
genotoxic effect (75-77). Cross-linking not only causes problems in terms of DNA isolation, 
but also reduces PCR amplification efficiency (25). Therefore, formaldehyde-induced cross-
linking reduces the overall stability of DNA (78), which makes downstream analysis difficult. 
 
3.5 DNA damage during preparation of FFPE blocks (physical stress) 
As mentioned above, formalin fixation has a time-dependent adverse effect on the quality of 
FFPET DNA and subsequent PCR results (79). Because different laboratories use different 
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fixation protocols and store tissues for different times, the quality of FFPET DNA should be 
checked prior to its use in clinical studies. Other than storage duration and fixation procedures, 
fixation time is another critical factor for PCR analysis. Indeed, Inoue et al. revealed that the 
quality of DNA in FFPET tissues varied markedly depending on the fixation time (79). It is 
imperative that all nucleic acid assays used for clinical purposes use properly prepared and 
stored FFPE tissues. However, many hospitals lack appropriate FFPET storage facilities, 
resulting in numerous unqualifiable samples (80). Thus, for successful assay in the clinic, DNA 
quality is paramount. Furthermore, prior to the use of FFPET samples aged more than 10 years 




3.6 Strategies for minimizing sequence artifact 
Minimizing sequence artifacts is critical for accurate detection of mutations in FFPET DNA. 
Accurate detection of EGFR-TKI actionable and/or resistance mutations enables identification 
of patients who will benefit from targeted therapy and avoid adverse effects associated with 
unnecessary treatment of non-responsive patients. Several strategies can be used to minimize 
DNA damage, which is the main limitation for any PCR-based assay and/or amplicon 
sequencing-based technique. Several papers describe strategies for minimizing sequence 
artifacts (Table. 4) (66, 81).  
First, fragmentation of FFPET DNA reduces the amount of amplifiable template available. 
As mentioned earlier, the success rate of PCR is related to amplicon size. Therefore, it is 
important to consider short amplicons when designing primers and probes (82, 83). In addition, 
the design of shorter amplicons as well as more stricter conditions for PCR amplification could 
be a useful way to lower the amount of unspecific PCR products, which generate of high 
background (81). Moreover, careful design of primers and probes are necessary to prevent non-
specific artefacts such as primer dimers and chimeric products. 
Second, C:G>T:A artifacts are a common form of damage found in FFPET DNA (84). In-
vitro removal of uracil bases from FFPET DNA using uracil-DNA glycosylase (UDG) before 
PCR amplification reduces this problem (84). Detection of true mutations is not affected by 
UDG treatment. UDG is an evolutionarily conserved DNA repair enzyme that imitates the base 
excision repair pathway and removes uracil from DNA (85). Thus, pre-treatment with UDG is 
a simple and effective strategy for reducing C:G>T:A artefacts.  
Third, reversal of formaldehyde-induced DNA-DNA and DNA-protein crosslinks by heating 
samples to over 90°C increases the amount of amplifiable DNA template (82, 86-88). 
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Lastly, template quantity and quality are crucial for optimizing assay conditions and accurate 
detection of mutations. The same measured quantity of different FFPET DNAs can contain 
different amounts of amplifiable template, depending on the degree of DNA fragmentation (59). 
Spectrophotometric and fluorometric methods tend to seriously overestimate the actual amount 
of amplifiable FFPET-DNA (69). Thus, PCR-based methods such as qPCR and digital (d)PCR 







1. Design shorter amplicons 
2. Assessment of DNA integrity 
3. Quantification of amplifiable templates using PCR 
Deamination 1. Pre-treatment with UDG 
Abasic sites 
1. Use of specific DNA polymerases (e.g. pfu polymerase) that 
have low bypass efficiency over DNA lesions such as uracil 
and abasic sites 
1. Use of a high-fidelity DNA polymerase to reduce polymerase 
errors 
Cross-linking  
1. Heat treatment of remove formaldehyde- induced crosslinks 
2. Extended proteinase K treatment to digest tissues and remove 
proteins cross-linked to DNA 
Physical stress 
1. Establishment of SOPs for sample storage conditions 
2. Establishment of SOPs for fixation procedures 
 




4. Liquid biopsy 
Direct testing of tumor tissue is used widely to detect gene mutations. However, methods 
used to determine mutation status in tumor tissue from patients with NSCLC have limitations 
(89). First, tumor samples are “contaminated” by normal tissue. Second, the biopsy may not 
represent the total burden of mutated cells, particularly in patients with metastatic disease. 
Third, the quality of extracted and stored DNA is variable; poor quality DNA may prevent 
accurate analyses. Also, patients with progressive disease cannot always be subjected to 
invasive procedures. In light of these limitations, new ways of monitoring tumor genetics and 
tumor dynamics have been developed. Recently, cell-free circulating tumor DNA (cfDNA and 
ctDNA) has attracted much attention as a potential tumor marker.  
Analysis of “liquid biopsies” is a rapidly expanding field of cancer research because it can 
be useful for diagnosis and treatment of cancer patients, as well as its non-invasive and 
convenience. Analysis of liquid biopsies enables [a] early diagnosis, [b] estimation of the risk 
of cancer recurrence and metastasis (prognostic information), [c] observation and real-time 
monitoring of treatment responses, [d] better understanding of the therapeutic target and 
mechanism(s) of resistance, and [e] better understanding of metastasis (90). 
However, it is unclear whether ctDNA in liquid biopsies can be used for non-invasive 
assessment of EGFR mutations in NSCLC patients. The first blood-based EGFR mutation 
analysis method to be developed was based on plasma obtained from pre-treatment NSCLC 
patients with gefitinib using the amplification refractory mutation system (ARMS)-based 
EGFR mutation detection kit. The EGFR mutation status derived from tumor tissue agreed 
with the results from matched plasma samples in 73% of cases (91). This result showed that it 
was possible to use ctDNA to detect EGFR mutations; other studies have also used various 
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serum- or plasma-based methods to assess EGFR mutation status (92-97). A previous paper 
reported the application of non-invasive procedures to monitor the EGFR T790M (98). 
Monitoring the mutation by using plasma in patients gives benefit to patients by suggesting 
proper treatment. 
Because ctDNA analysis does not involve formaldehyde fixation, the number of false-
positive results (caused by deamination) is low (99). Also, the amount of ctDNA in the plasma 
of healthy controls is much lower than that in NSCLC patients (100, 101). However, it is very 
difficult to analyze ctDNA from NSCLC patient due to the low amount of absolute ctDNA. 
The frequent fragmentation is another obstacle for analysis. It is known that double-stranded 
DNA fragmentations frequently occur in the serum or plasma of cancer patients (102). Also, 
high levels of DNA derived from tissues of non-tumor origin make detection of ctDNA 
technically difficult. Since ctDNA is derived directly from the tumor, it must be quantified 
accurately and with high sensitivity (103-108). Due to the varying quantity and quality of DNA 
derived from tumors, high sensitive and specialized equipment is required for ctDNA detection. 
Cutting-edge technologies can be used to detect somatic mutations, loss of heterozygotes, and 
mutation of tumor associated genes, at low frequencies as low as 0.01% (109-113). Although 
several methods can be used to analyze mutations in ctDNA [e.g., digital polymerase chain 
reaction (dPCR) (114), mutant-enriched PCR, and peptide nucleic acid-locked nucleic acid 





5. Third generation PCR: Droplet digital PCR (ddPCR) 
 
Real-time quantitative PCR (qPCR) is the most common method used to quantify expression 
of target genes (115, 116). However, either external calibrators or normalization to endogenous 
controls is required to estimate the concentration of an unknown (117). Imperfect amplification 
efficiency affects CT  values, which in turn limits the accuracy of this technique for absolute 
quantitation. ddPCR is an assay that combines state-of-the-art microfluidics technology with 
TaqMan-based PCR to achieve precise identification of target DNA with high sensitivity and 
specificity (Fig. 5, Table. 5) (118). This is because quantitation is achieved without the need 
for standard assays, allowing easy interpretation and an unambiguous digital readout. For 
ddPCR, a sample is fractionated into 20,000 droplets and PCR amplification of the template 
molecule(s) occurs in each individual droplet, effectively avoiding PCR bias, increasing the 
signal to noise ratio, removing the need for calibration or a reference, and providing absolute 
quantitation of a sample (117, 119). Hence, ddPCR is far simpler, faster, and less error prone 
than qPCR (120). Due to its technological advantages, which enable highly sensitive detection 
of mutations, the method has been adopted for clinical research (97, 119, 121-123). Notably, 






Figure 5. Schematic showing the ddPCR workflow. (A) Sample preparation and droplet 





 Real time-PCR ddPCR 
Advantage 1. High throughput, routine experiments 
2. Relative quantification 
3. Short run time (~2 h / 96 samples) 
4. Low running cost  
1.  High Accuracy, Precision, Sensitivity                        
    (reduced error rate, 1.2-fold ↓) 
2.  Relative and absolute quantification 
3.  Simplified quantification  
    : neither calibration standards nor a reference is required 
4.  Removal of PCR bias 
5.  Superior partitioning  
    : 20,000 droplets per 20 μl  higher accuracy 
6.  Sensitive detection of molecules with low-expression 
Disadvantage 1. Dependent on CT  value of calibration 
standards 
2. Inhibitor-dependent PCR efficiency 
1. Long run time (6 h / 96 samples) 
2. Higher running costs 
3. Requires attention compared to qPCR 
 




6. Limit of blank, limit of detection and limit of quantitation 
In the field of diagnostics, the ability to detect slight alterations in DNA is very important. 
This is known as sensitivity. Sensitivity is an important characteristic of any diagnostic tool 
because the ability to detect low level mutations increases the reliability of the assay. Sensitivity, 
limit of blank (LoB), limit of detection (LoD), and limit of quantitation (LoQ) are related by 
means of describing the lowest concentration of analytes (Fig. 6). 
 
6.1 Limit of blank (LoB) 
LoB is used when testing the samples that contain no analyte. It is a measure of a sample’s 
expected maximum analyte concentration. Even though the samples lack analytes, the blank 
might contain low concentration of analytes. This is important when using very sensitive 
methods such as ddPCR. The LoB in ddPCR rules out false-positives. Therefore, it is very 
important to measure the LoB using standard guidelines. 
LoB is estimated by blank sample’s mean result and standard deviation (SD). The LoB is 
calculated according to:  
LoB = mean blank + 1.645 (SD blank) 
 
6.2 Limit of detection (LoD) 
LoD is the lowest analyte concentration and it is reliable. Opposite to LoB, which 
measures the highest concentration of analytes, LoD measures the lowest analyte concentration. 
LoD is an interval where analytes are detected while performing serial dilution. The LoD is 
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calculated by mean and SD of the low concentration of sample. The LoD is calculated 
according to:  
 
LoD = LoB + 1.645 (SD low concentration sample) 
 
 
6.3 Limit of quantitation (LoQ) 
LoQ is not only an analyte that can be reliably detected, but it is also the lowest 
concentration indicator for functional sensitivity. The LoQ value can be greater or equal to the 
LoD, even though the LoQ and LoD are calculated independently. In clinical trials, the LoQ 
indicates the minimal sensitivity to drug. 
The Clinical and Laboratory Standards Institute (CLSI) have published standard guidelines 
for determining the LoB, LoD, and LoQ (CLSI document EP17. Wayne, PA USA: CLSI; 2004). 
It is important to characterize the analytical performance of diagnostics tests to understand their 







Figure 6. Relationship between the LoB, LoD, and LoQ. Distribution of replicates of a blank 
sample (solid black curve) and a specimen of low concentration (blue dashed curve). The LoB 
excludes a small proportion of blank results (“α”, Type I error). The LoD is then set such that 
only a small proportion (“β”, Type II error) of these results will fall below the LoB. A sample 
measurement result exceeding the LoD threshold would represent quantitative detection of the 















Advances in science and technology have opened up new avenues in terms of molecular 
targeted therapy for cancer patients. For instance, several signal transduction pathways are 
activated in various cancers, which can be targeted by small molecules. Mutation analysis is a 
key factor for stratifying cancer patients according to the likely benefit of molecular targeted 
therapy. Therefore, accurate detection of mutations that may aid/retard cancer therapy is 
essential.  
Imprecise mutation analysis caused by DNA damage is a very serious problem in many 
diagnostic fields. In particular, DNA fragmentation reduces the amount of amplifiable DNA in 
a tissue; this makes estimation of the mutation frequency value (based on the amount of input 
DNA) less accurate. FFPET is the most widely used resource for mutation analysis. But, 
artifactual sequence variants arising from DNA damage will be detected more frequently 
because stochastic enrichment (in the context of low copy targets) increases the risk of false-
positives. DNA extracted from FFPET is subject to extensive fragmentation, which reduces 
data quality. None of the traditional tools used to check DNA integrity (e.g., UV absorbance or 
gel electrophoresis) actually measure the amount of amplifiable DNA or the amount of DNA 
fragmentation. Therefore, information on the PCR amplifiable templates will enable 
determining how reliable the accuracy of detected gene mutation.  
Here, we report development of sample criteria to ensure minimum FFPET DNA quality for 
PCR. We then apply these criteria to a ddPCR-based EGFR mutation test. To establish the 
sample criteria, we first collected and analyzed 316 NSCLC FFPET DNA samples of various 
age and quality from three different sites (hospitals). We also conducted independent 
retrospective clinical studies using 228 NSCLC FFPET samples to verify the clinical 
implications of the established sample criteria. In addition, we compared the performance of 
the GenesWell™ ddEGFR mutation test (ddEGFR test) with that of the Cobas®  EGFR mutation 
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test (Cobas EGFR test) in a pre-clinical and clinical studies based on 544 NSCLC FFPET 
samples.  
The major study objectives were 1) to establish sample criteria to determine the minimum 
DNA quality suitable for PCR, 2) to compare the clinical performances of the ddEGFR and 
















1. Study design 
To establish sample criteria, a total of 316 samples obtained from NSCLC patients were 
tested for EGFR mutations. A post-hoc analysis of these pre-clinical data was conducted for 
both the ddEGFR and cobas EGFR test results (Fig. 7). Based on the established sample criteria, 
an independent retrospective comparison study was performed to estimate the concordance 
between the ddEGFR and cobas EGFR tests; for this purpose, 228 FFPET-DNA samples from 
NSCLC patients were analyzed by both tests (Fig. 8). Both EGFR mutation tests were 
performed in a double-blind fashion by an independent laboratory (Abion Inc., Seoul, Korea). 









Figure 7. Study design and specimen selection (work flow of pre-clinical study). Patient 
sample dispositions for the applied sample criteria. For the pre-clinical study group, a total of 








Figure 8. Study design and specimen selection (work flow of retrospective comparison 
study). Patient sample dispositions for the applied iQC index. For the retrospective comparison 




2. FFPET collection  
FFPET blocks of resected or biopsy samples from NSCLC patients (n = 316) collected from 
2005 to 2014 were retrieved from the Department of Pathology, Samsung Medical Center (n = 
200) (SMC; Seoul, Korea), Asan Medical Center (n = 66) (AMC; Seoul, Korea), and Severance 
Hospital (n = 50) (Seoul, Korea). This study was approved by the Institutional Review Board 
(IRB) of SMC and Seoul National University (study ID: SMC-2014-05-084-002). For the 
retrospective comparison study, 228 archived FFPET blocks from NSCLC patients collected 
between 2010 and 2016 were obtained from Department of Pathology, SMC. This study was 
approved by the IRB of SMC and the Ministry of Food and Drug Safety (MFDS) of Korea 
(study ID: SMC-2016-07-104-002). From each FFPET, 10 μm sections were cut and subjected 
to DNA extraction. H&E-stained sections containing tumor lesions marked by a pathologist 
(S.W.C.) were scanned, and the cancer/normal (C/N) ratio was calculated using the Pannoramic 
Viewer Software v.1.15.4 (3DHISTECH, Budapest, Hungary). Patient information was 
anonymized and de-identified prior to analysis. 
 
3. DNA extraction and determination of DNA quantity and quality 
DNA extraction from FFPETs was performed using an automated Tissue Preparation System 
(TPS; Siemens Healthcare, Erlangen, Germany) with the VERSANT®  Tissue Preparation 
Reagents, as described previously (124). Total nucleic acids were eluted with 100 μL elution 
buffer containing UDG provided by the manufacturer. For all samples, DNA concentration was 
assessed using the Qubit™ 3.0 Fluorometer and Qubit dsDNA BR assay kit (ThermoFisher 
Scientific, MA, USA). The DNA integrity number (DIN), reflecting the DNA fragmentation 
level (125) of genomic DNA (gDNA), was analyzed on a 2200 TapeStation system with 
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Genomic DNA Screen Tape (Agilent Technologies, CA, USA). The samples were prepared by 
mixing 1 μl of DNA sample with 10 ul of genomic DNA sample buffer. A genomic DNA ladder 
was placed in the first lane of 8-strip tube followed by the samples. The prepared strip tube was 
mixed and placed in the 2200 TapeStation instrument. Samples were analyzed using 
TapeStation Analysis v.01.15 Software. 
 
4. Validation of internal quality control (iQC) of ddEGFR test 
The ddEGFR test (Gencurix Inc., Seoul, Korea) was designed as a highly sensitive ddPCR-
based diagnostic test for detecting 45 mutation sites within the exon 18–21 region of the EGFR 
gene using four reactions. The amplified fragments, which contain the fluorophores FAM™ or 
HEX™, are displayed as dots (droplets) and can be used to calculate concentrations (copies/20 
μL) based on the Poisson distribution (118). The details of specific mutations detected by the 










Target mutant A.a Target mutant site Result 
1 
Exon18 
6239 p.G719A c.2156G>C 
G719X 2 6252 p.G719S c.2155G>A 
3 6253 p.G719C c.2155G>T 
4 
Exon19 
6223 p.E746_A750del c.2235_2249 del 15 
19del 
5 13551 p.E746_T751>I c.2235_2252 > AAT 
6 12728 p.E746_T751del c.2236_2253 del 18 
7 12678 p.E746_T751>A c.2237_2251 del 15 
8 12367 p.E746_S752>A c.2237_2254 del 18 
9 12384 p.E746_S752>V c.2237_2255>T 
10 6225 p.E746_A750del c.2236_2250 del 15 
11 6220 p.E746_S752>D c.2238_2255 del 18 
12 13550 p.E746_A750>IP c.2235_2248>AATTC 
13 12403 p.L747_S752>Q c.2239_2256>CAA 
14 12422 p.L747_A750>P c.2238_2248 >GC 
15 12419 p.L747_T751>Q c.2238_2252 >GCA 
16 6218 p.L747_E749del c.2239_2247 del 9 
17 12382 p.L747_ A750>P c.2239_2248 TTAAGAGAAG>C 
18 6210 p.L747_T751>S c.2240_2251 del 12 
19 12383 p.L747_T751>P c.2239_2251>C 
20 13552 p.E746_T751>IP c.2235_2251>AATTC 
21 6254 p.L747_T751del c.2239_2253 del 15 
22 6255 p.L747_S752del c.2239_2256 del 18 
23 12387 p.L747_P753>Q c.2239_2258 >CA 
24 12370 p.L747_P753>S c.2240_2257 del 18 
25 12416 p.E746_T751>VA  c.2237_2253>TTGCT 
26 - - c.2239_2257>GT 
27 26038 p.K745_E749del c.2233_2247del15 
28 13556 p.S752_I759del c.2253_2276del24 
29 12386 p.E746_T751>V c.2237_2252>T 
30 12385 p.E746_S752>I c.2235_2255>AAT 
31 18427 p.E746_P753>VS c.2237_2257>TCT 
32 12369 p.L747_T751del c.2240_2254 del 15 
33 23571 p.L747_T751delLREAT c.2238_2252 del 15 
34 
Exon20 
12376 p.V769_D770insASV c.2307_2308 insGCCAGCGTG 
E20Ins  
35 12377 p.H773_V774insH c.2319_2320 insCAC 
36 12378 p.D770_N771insG c.2310_2311 insGGT 
37 13428 p.D770_N771insSVD c.2311_2312insGCGTGGACA 
38 13558 p.V769_D770insASV c.2309_2310AC>CCAGCGTGGAT 
39 
Exon20 
6241 p.S768I c.2303G>T S768I 
40 6240 p.T790M c.2369C>T T790M 
41 - p.C797S c.2389T>A C797S 
40 
 
42 - p.C797S c.2390G>C 
43 
Exon21 
6224 p.L858R c.2573T>G 
L858R 
44 12429 p.L858R c.2573_2574TG>GT 
45 6213 p.L861Q c.2582T>A L861Q 
 
* Catalogue of Somatic Mutations in Cancer (COSMIC). 2016, v.78. 
   http://cancer.sanger.ac.uk/cosmic 
 




The non-clinical performance studies followed the guidelines approved by the Clinical and 
Laboratory Standards Institute (CLSI) and the Korea-MFDS. For validation of internal quality 
control of ddEGFR, FFPE reference standard DNA extracts (HDx™ Reference Standard, 
Horizon Discovery, Cambridge, UK) for EGFR mutations were blended with fixed amounts of 
wild-type gDNA (3.3 ng, 1000 GE; Promega) and each sample, with a target MI of 1.5%. In 
addition, four serial dilutions of each sample (9.9 ng, 6.6 ng, 3.3 ng, and 1.65 ng) were prepared 
and analyzed using the ddEGFR test. The iQC copies and target MI of each sample was 
confirmed based on the input DNA concentration and target MI (1.5%).  
 
5. Biomarker analysis 
The ddEGFR test was performed in a 20 μL volume containing 3.3 ng (1000 GE)/reaction 
of template DNA on a Droplet Digital™ PCR (ddPCR) system (Bio-Rad, Hercules, CA, USA). 
The ddPCR assay was conducted as described previously (124). Amplification conditions 
consisted of a 10 min activation period at 95 °C, followed by 40 cycles of a 30 sec at 94 °C for 
denaturation, 1 min at 60 °C for annealing/extension, and a final 10 min inactivation step at 
98 °C. After thermal cycling, plates were transferred to a QX200 droplet reader to read the 
droplets using the QuantaSoft v1.7.4 software (Bio-Rad) to assess the number of droplet 
positive for EGFR. Thresholds for detection were set manually based on results from non-
template control wells and negative control wells containing wild-type gDNA (Promega).  
PCR amplification for the cobas EGFR test (Roche Molecular Systems Inc., Branchburg, 
NJ, USA) was performed on a cobas®  z 480 Analyzer. The cobas EGFR test requires 150 ng 
total input DNA. The mutation result reporting is fully automated, mutation was reported as 
either G719X in exon 18, 19del in exon 19, S768I in exon 20, T790M in exon 20, exon 20 
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insertion, or L858R in exon 21 (126). Both mutation tests were analyzed in a double-blind 
fashion, and the results were matched after analysis.  
For mutation screening of EGFR exons 18, 19, 20, and 21 by 2× bidirectional Sanger 
sequencing, regions of interest were amplified by PCR, and the amplified samples were 
processed at an independent laboratory (Macrogen, Seoul, Korea) using a validated protocol.  
Sanger sequencing results were cross-checked and interpreted by a pathologist (Y.L.C). 
 
6. Methods correlation and statistical analysis 
Positive percent agreement (PPA), negative percent agreement (NPA), and overall percent 
agreement (OPA) of the ddEGFR and cobas EGFR tests were compared in pre-clinical and 
retrospective comparison studies. Agreement analysis for all methods was based on mutation 
report calls (Table. 7). Statistical analysis was performed using GraphPad Prism™ (GraphPad 
Software Inc., San Diego, USA) and the R 1.6.12 package ‘psych’ (http://CRAN.R-
project.org/package=psych). For the agreement analyses, PPA, NPA, and OPA were calculated 













1. Validation of internal quality control (iQC) of ddEGFR test  
Because the ddPCR-based test can lead to the false positive results by both its intrinsic high 
sensitivity and FFPET characteristics, the cut-offs of ddEGFR test were determined based on 
false-positive analyses using normal FFPET. Mutation calls were identified based on true-
positive mutation values higher than limit of blank (LoB) and limit of detection (LoD) mutation 
index (MI) [1], which were established by analytical performance studies (Table. 7). MI is a 
numerical value representing the ratio of mutant to internal quality control (iQC) copies, 
calculated as follows:  
MI (%) = [Mutant copies / iQC copies] × 100    [1] 
In the ddEGFR test, iQC copies can be converted to concentration of input DNA using an FFPE 
reference standard, suggesting that iQC index [2] is a representative index of amplifiable DNA. 
Because iQC copies were analyzed using 3.3 ng (1,000 genomic equivalents [GE]) of input 
DNA per reaction well, iQC index was calculated as follows: 
iQC index = [iQC copies / input DNA copies]    [2] 
An iQC index value close to “1” means that the quality of DNA is better. Figure 9 shows the 
concept and example of iQC index. 
Using 40 wild-type FFPET samples, false-positive rates were determined for mutant calling of 
eight targets. The maximum number of copies was 5.4 per reaction, and the false-positive rates 





Exon Mutations detected Mutation report call LoB copies / MI (% ) * 
LoD MI (% ) 
† 
18 G719A, G719C, G719S G719X 5.6 / 0.22 0.77 
19 30 deletions 19del 3.0 / 0.09 0.83 
20 S768I S768I 1.5 / 0.05 0.83 
 T790M T790M 6.8 / 0.34 0.78 
 C797S § C797S 1.6 / 0.03 0.75 
  5 Insertions E20Ins 1.6 / 0.06 0.62 
21 L858R L858R 1.6 / 0.03 0.71 
  L861Q L861Q 1.4 / 0.05 0.74 
 
* LoB = mean blank + 1.645 (SD blank) (127) 
† LoD MI (%) = mean low concentration sample + 1.645 (SD low concentration sample) 
§ using the plasmids containing the non-predominant mutation for analytical performance 
 
Table 7. ddEGFR test coverage. The test is designed to detect G719X (G719A, G719C, and 
G719S) mutations in exon 18, deletions, complex mutations (S768I, T790M, and C797S) in 
exon 19, insertions in exon 20, and the L858R and L861Q mutations in exon 21. The LoB were 
calculated using 9.9 ng of normal FFPET-DNA. The LoD was measured 6 points (3-0.1%) 
serially diluted using the NSCLC FFPET-DNA (19del, L858R) and reference standard FFPET-
DNA (the other mutations) with wild-type FFPET-DNA. The LoD was determined by the 








Figure 9. The concept of iQC index. iQC copy reflects the amount of amplifiable DNA. The 
amount of amplifiable DNA is represented as an iQC index compared to the proportion of input 










Figure 10. Determination of a suitable cut-off based on false-positive analysis using 
normal FFPET blocks. Forty normal FFPET specimens were tested, and eight targets were 
evaluated for each specimen. The maximum number of copies was 5.4 per reaction (red dotted 




We evaluated iQC using reference standard. Reference standard FFPET-DNA extract for 
EGFR mutations was blended with fixed amount of wild-type gDNA (3.3 ng, 1,000GE) 
targeting a 1.5% mutation level. The expected iQC index and MI were given by the calculated 
from the quantity of input DNA. As a result, the measured MI (%) and iQC index were 
observed close to match with expected value (iQC index = 1, MI = 1.5%) (Fig. 11). Moreover, 
iQC was also validated by serial dilution with four concentrations of reference standard FFPET-
DNA, and observed that the measured values close match with the each expected values (Fig. 







Figure 11. Validation of internal quality control of ddEGFR test (MI validation). Internal 
quality control (iQC) validation using reference standard. Each FFPE reference standard DNA 
extract for the EGFR mutations was blended with a fixed amount of wild-type gDNA (3.3 ng, 
1000GE) targeting a 1.5% mutation level, which was validated for use in the ddEGFR test. 



























































Figure 12. Validation of internal quality control of ddEGFR test (iQC copy and iQC 
index). Internal quality control (iQC) validation using the reference standard. Four serial 
dilutions of each FFPET reference standard DNA extract were prepared and subjected to the 


















































































2. Comparison of ddEGFR and cobas EGFR tests without sample criteria 
The EGFR mutations in 316 NSCLC FFPET samples were analyzed using the 
ddEGFR and cobas tests. Both methods yielded valid results for all but one of the samples. 
Surprisingly, the ddEGFR and cobas EGFR tests were low concordant (PPA = 94.04%, NPA = 
63.41%, OPA = 78.10%, kappa coefficient value (κ) = 0.6650) (Table. 8, Table. 9). The cobas 
EGFR test also exhibited very low concordance with Sanger sequencing of 299 samples (PPA 





(n = 316) 
cobas EGFR Test 
MD MND Total 
ddEGFR 
Test 
MD 139 62 * 201 
MND 9 104 113 
Total 148 166 314 
 
PPA (95% C.I.) 94.04% (88.99−97.24%) 
NPA (95% C.I.) 63.41% (55.55−70.79%) 
OPA (95% C.I.) 78.10% (73.12−82.54%) 
PPV (95% C.I.) 70.30% (63.48−76.51%) 
NPV (95% C.I.) 92.04% (85.42−96.29%) 
 
* 3 samples: cobas, 19del; ddEGFR, 19del/T790M 
   1 sample: cobas, 19del; ddEGFR, 19del/L858R 
   1 sample: cobas, E20Ins; ddEGFR, E20Ins/T790M 
   1 sample: cobas, S768I; ddEGFR, S768I/L858R 
 
Table 8. A total of 316 samples with valid ddEGFR and cobas EGFR test results were 
included in the agreement analysis. PPA, NPA, and OPA between the ddEGFR and cobas 





† 1 sample was excluded from the analysis, 1 sample: Invalid 
ĸ coefficient = 0.6650 (95% C.I. 59.98−73.03%) 
Table 9. Detail concordance table of 316 samples with valid ddEGFR and cobas EGFR test. 
All Samples 
(n = 316) 
cobas EGFR Test 


















G719X 1             1 2 
19del  85            4 89 
T790M   0            0 
E20Ins    0          2 2 
S768I     0          0 
L858R  1 †    48        47 96 
G719X,T790M       0       1 1 
G719X,S768I        3       3 
19del,T790M  3       0      3 
19del,L858R  1        0     1 
T790M,L858R           0   1 1 
T790M,E20Ins    1        0   1 
S768I, L858R     1        2  3 
MND  9            104 113 




(n = 299) 
Sanger sequencing 
MD MND Total 
cobas 
EGFR test 
MD 102  29 * 131 
MND  70 † 87 157 
Total 172 116 288 
 
PPA (95% C.I.) 59.30% (61.56−66.72%) 
NPA (95% C.I.) 75.00% (66.11−82.57%) 
OPA (95% C.I.) 65.63% (59.83−71.10%) 
PPV (95% C.I.) 77.86% (69.78−84.65%) 
NPV (95% C.I.) 55.41% (47.28−63.34%) 
 
* 1 sample: Sanger, L858R; cobas, L858R, S768I 
† 4 samples: Sanger, 19del, L858R; cobas, 19del 
1 sample: Sanger, 19del, L858R; cobas, L858R 
 
Table 10. Concordance of EGFR mutation detection between the cobas EGFR test and 
Sanger sequencing, without application of exclusion criteria. A total of 299 samples with 
valid Sanger sequencing and cobas EGFR test results were included in the analysis. Seventeen 





§ 11 samples were excluded from the analysis 
ĸ coefficient = 0.4526 (95% C.I. 37.45−53.07%) 
Table 11. Detail concordance of EGFR mutation detection between the cobas EGFR test and Sanger sequencing, without application of 
exclusion criteria. 
All samples 
(n = 299) 
Sanger Sequencing 

















G719X 0             1 1 
19del  62    8 §   4     18 92 
T790M   0            0 
E20Ins    0          1 1 
S768I     0          0 
L858R  2 §    40   1     5 48 
19del,G719X       0        0 
19del, T790M        0       0 
19del, L858R         0      0 
G719X,T790M          0     0 
G719X,S768I  1 §         0   2 3 
T790M,L858R            0   0 
S768I, L858R      1       0 1 2 
MND  24    27 1  13     87 152 
Total 0 89 0 0 0 76 1 0 18 0 0 0 0 115 299 
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3. Proof-of-concept for determination of minimum DNA quality suitable for PCR using 
the ddPCR method 
 
To increase the concordance between the ddEGFR and cobas EGFR tests, we investigated 
the minimum DNA quality suitable for PCR analysis by re-analyzing the ddEGFR data, which 
provided iQC copies and index (Fig. 11, 12). FFPET block storage duration was reflected in 
the amount of amplifiable DNA, decreasing below 50% (mean of iQC index = 0.31, Standard 
deviation, SD = 0.57) of 1000 GE in 7–11-year-old samples. By contrast, in 26-year-old 
samples, the amount of amplifiable DNA was around 100% (mean of iQC index = 1.07, SD = 
0.69) (Fig. 13). Therefore, iQC index decreased with storage duration when FFPET was stored 
at room temperature. The pattern of DIN values from 315 FFPET-DNA samples measured in 






Figure 13. Distributions of ddEGFR iQC index corresponding to sample storage time. 











Figure 14. Distributions of DIN value corresponding to sample storage time. The black 





4. Establishment of iQC index for ddEGFR using FFPET samples 
We classified all 316 samples into four groups according to their storage durations, DIN 
values, and iQC copies, as illustrated in Figure 4A. First, we analyzed DIN values for 57 
discordant samples from among 169 samples derived from blocks stored for more than 6 years. 
The DIN value was less than 2.5 for most of the discordant samples (Fig. 15). Among 147 
samples with a block storage duration ≤ 6 years, 26 samples did not satisfy our DIN criteria, 
and were included in Group 1 (Table 12, Table 13). To establish iQC index criteria, the 60 
discordant samples in Group 1 were re-analyzed, and almost all (58/60) had an iQC index < 
0.5 (Fig. 16).  
Based on this result, the sample criteria were established as follows: block storage 
duration ≤ 6 years, DIN > 2.5, and iQC index ≥ 0.5. In addition, we observed a strong 
correlation between ddEGFR iQC index and DIN value, further supporting the idea that iQC 








Figure 15. Establishment of sample criteria using discordant samples (DIN value). 
Discordant samples were analyzed by comparing the results of the Cobas EGFR and ddEGFR 
tests. Plots show distributions of the correlation between DIN value and sample storage 
duration of discordant samples. The black line represents the median value. The DIN values of 







Figure 16. Establishment of sample criteria using discordant samples (iQC index). 
Discordant samples were analyzed by comparing the results of the Cobas EGFR and ddEGFR 
tests. Plots show distributions of the correlation between iQC index and sample storage 
duration of discordant samples. The black line represents the median value. The iQC index of 




Group 1 (n = 194) 
cobas EGFR Test 
MD MND Total 
ddEGFR 
Test 
MD 49   56 * 105 
MND 9 79 88 
Total 58 135 193 
 
PPA (95% C.I.) 84.48% (72.58% to 92.65%) 
NPA (95% C.I.) 58.52% (49.73% to 66.93%) 
OPA (95% C.I.) 66.32% (59.18% to 72.95%) 
PPV (95% C.I.) 46.67% (36.87% to 56.66%) 
NPV (95% C.I.) 89.77% (81.47% to 95.22%) 
 
 
Table 12. Comparison of ddEGFR and cobas EGFR results from FFPE samples  (block 
storage duration > 6, DIN < 2.5). PPA, NPA, and OPA between the ddEGFR and cobas EGFR 
tests for the detection of EGFR mutations were 84.48%, 58.52%, and 66.32%, respectively. 




(n = 194) 
Cobas EGFR Test 



















G719X 0              0 
19del  33            3 36 
T790M   0            0 
E20Ins     0          1 1 
S768I     0          0 
L858R  1 †    14        44 59 
G719X,T790M       0       1 1 
G719X,S768I        1       1 
19del,T790M  3       0      3 
19del,L858R  1        0     1 
T790M,L858R           0   1 1 
T790M,E20Ins    1        0   1 
S768I, L858R     1        1  2 
N/A  9            79 88 
Total 0 47 0 1 1 14 0 1 0 0 0 0 1 129 194 
ĸ coefficient = 0.4611 (95% C.I. 36.56−55.66%) 
 







Table 14. Correlation between ddEGFR iQC index and DIN value. The ddEGFR iQC index 
and DIN value of excluded samples were lower than the values of the sample criteria. Results 
from included samples were opposite to those of the excluded samples. In addition, the 




5. Comparison of ddEGFR and cobas EGFR tests with iQC index criteria  
 
When the iQC index cut-off was applied to 121 samples (block storage duration ≤ 6 years, 
DIN > 2.5), 113 samples remained (Fig. 7, Group 2). Group 2 samples had a very high 
concordance rate between the ddEGFR and cobas EGFR tests (PPA = 100.00%, NPA = 76.00%, 
OPA = 94.69%, κ = 0.9197) (Table. 15, Table. 16). To determine the clinical implications of 
the iQC index, we applied this criterion to 316 FFPETs, resulting in the classification of 150 
samples into Group 3 (Fig. 7), and re-analyzed the concordance rate between the ddEGFR and 
cobas EGFR results. Group 3 samples had a very high concordance rate (PPA = 100.00%, NPA 
= 75.00%, OPA = 92.67%, κ = 0.8923) (Table. 17, Table. 18), similar to the results from Group 
2 (applying all criteria). By contrast, Group 4 samples, in which the iQC index criterion was 
not satisfied, exhibited a very low concordance rate (PPA = 78.57%, NPA = 58.20%, OPA = 
63.41%, κ = 0.3862) (Table. 19, Table. 20). Therefore, we suggested that iQC index is a key 









(n = 113) 
cobas EGFR Test 
MD MND Total 
ddEGFR Test 
MD 88 6 94 
MND 0 19 19 
Total 88 25 113 
 
PPA (95% C.I.) 100.0% (95.89−100.0%) 
NPA (95% C.I.) 76.00% (54.87−90.64%) 
OPA (95% C.I.) 94.69% (88.80−98.03%) 
PPV (95% C.I.) 93.62% (86.62−97.62%) 
NPV (95% C.I.) 100.0% (82.35−100.0%) 
MD, mutation detected; MND, mutation not detected 
 
Table 15. Comparison of ddEGFR and cobas EGFR results from FFPE samples 
eliminated by the sample criteria (DIN and iQC index). Analysis of concordance rates 
between ddEGFR and cobas EGFR tests when the sample criteria were applied (Group 2). PPA, 
NPA, and OPA between the ddEGFR and cobas EGFR tests for the detection of EGFR 
mutations were 100%, 76.00%, and 94.69%, respectively. MD, mutation detected; MND, 




ĸ coefficient = 0.9197 (95% C.I. 85.85−98.09%) 
Table 16. Comparison between the ddEGFR and cobas EGFR test results with application of the sample criteria (Group 2). 
  
Group 2 
(n = 113) 
cobas EGFR Test 










G719X 1         1 2 
19del  51        1 52 
T790M   0        0 
E20Ins    0      1 1 
S768I     0      0 
L858R      33    3 36 
G719X, 
T790M 
      0    0 
G719X, 
S768I 
       2   2 
S768I, 
L858R 
        1  1 
MND          19 19 
Total 1 51 0 0 0 33 0 2 1 25 113 
68 
 
* 3 samples: cobas, 19del; ddEGFR, 19del/T790M  
 
Table 17. Comparison of ddEGFR and cobas EGFR results from FFPE samples 
eliminated by the sample criteria (iQC index only). Analysis of concordance rates between 
ddEGFR and cobas EGFR tests when the sample criteria were applied (Group 3). PPA, NPA, 
and OPA between the ddEGFR and cobas EGFR tests for the detection of EGFR mutations 
were 100%, 75%, and 92.67%, respectively. MD, mutation detected; MND, mutation not 
detected.
Group 3 
(n = 150) 
cobas EGFR Test 
MD MND Total 
ddEGFR Test 
MD 106  11 * 117 
MND 0 33 33 
Total 106 44 150 
 
PPA (95% C.I.) 100.0% (96.58−100.0%) 
NPA (95% C.I.) 75.00% (59.66−86.81%) 
OPA (95% C.I.) 92.67% (87.26−96.28%) 
PPV (95% C.I.) 90.60% (83.80−95.21%) 




ĸ coefficient = 0.8923 (95% C.I. 83.25−95.22%) 
Table 18. Comparison between the ddEGFR and cobas EGFR test results, with application of only the iQC criterion (Group 3). 
 
Group 3 
(n = 150) 
cobas EGFR Test 











G719X 1          1 2 
19del  61         1 62 
T790M   0         0 
E20Ins    0       1 1 
S768I     0       0 
L858R      41     4 45 
G719X,T790M       0    1 1 
G719X,S768I        2    2 
19del,T790M  3       0   3 
S768I, L858R          1  1 
MND           33 33 




(n = 166) 
cobas EGFR Test 
MD MND Total 
ddEGFR 
Test 
MD 33 51 * 84 
MND 9 71 80 
Total 42 122 164 
 
PPA (95% C.I.) 78.57% (63.19−89.70%) 
NPA (95% C.I.) 58.20% (48.93−67.06%) 
OPA (95% C.I.) 63.41% (55.55−70.79%) 
PPV (95% C.I.) 39.29% (28.80−50.55%) 
NPV (95% C.I.) 88.75% (79.72−94.72%) 
 
* 1 sample: cobas, 19del; ddEGFR, 19del/L858R 
   1 sample: cobas, E20Ins; ddEGFR, E20Ins/T790M 
   1 sample: cobas, S768I; ddEGFR, S768I/L858R 
 
Table 19. Re-analysis of concordance rate using excluded samples. Samples were selected 
by iQC index (< 0.5). The 166 excluded samples with valid ddEGFR test and cobas EGFR test 
results were included in the agreement analysis. PPA, NPA, and OPA between the ddEGFR and 




† 1 sample was excluded from the analysis, 1 sample: invalid 
ĸ coefficient = 0.3862 (95% C.I. 27.85−49.40%) 
Table 20. Detail concordance rate using excluded samples. Samples were selected by iQC index (< 0.5). The 166 excluded samples with valid 
ddEGFR test and cobas EGFR test results were included in the agreement analysis. 
Group 4 
(n = 166) 
cobas EGFR Test 


















G719X 0              0 
19del  24            3 27 
T790M   0            0 
E20Ins    0          1 1 
S768I     0          0 
L858R  1 †    7        43 51 
G719X, 
T790M 
      0        0 
G719X, S768I        1       1 
19del,T790M         0      0 
19del,L858R  1        0     1 
T790M,E20Ins    1       0    1 
T790M,L858R            0  1 1 
S768I, L858R     1        1  2 
N/A  9            71 80 
Total 0 35 0 1 1 7 0 1 0 0 0 0 1 119 165 
72 
 
6. Analysis of discordant samples in pre-clinical study 
Applying the iQC index criterion, we re-analyzed the remaining 11 discordant samples in 
Group 3. A schematic representation of the re-analysis workflow for discordant samples is 
depicted in Figure 17. In three of the samples, the ddEGFR test reported a double mutation 
(19del/T790M), whereas the cobas EGFR test and Sanger sequencing reported only a single 
mutation (19del) (Table 17, Group 3). This may be a result of the low detection sensitivity of 
Sanger sequencing (around 15%) (128) and cobas EGFR tests (LoD of T790M = ~ 3%; cobas 
EGFR v2). Based on the ddEGFR results of these three samples, the MI of T790M was ~1% 
(1.11%, 1.16%, and 1.03%). Additionally, eight discordant samples were verified by Sanger 
sequencing, and no mutations were found (Table. 21). Moreover, to observe the effect of tumor 
ratio, we performed macrodissection to enrich for tumor tissue, and then re-analyzed EGFR 
mutations in eight samples for which the cobas EGFR test had yielded negative results but the 
ddEGFR test yielded positive results. After macrodissection, the cobas EGFR test gave the 
same results as the ddEGFR test for four of the eight samples (Table. 21). Thus, our results 
indicate that the ddEGFR test is more sensitive for EGFR mutation detection, independent of 
tumor ratio. Strangely, one discordant case was a mutation detected (T790M/G719X) of 
preliminary result, whereas invalid by the ddEGFR test after macrodissection. Because iQC 
index is very low (0.37, data not shown), it is estimated that DNA degradation progressed 








Figure 17. Schematic of re-analysis of discordant samples. Eight of eleven discordant 
samples were verified by Sanger sequencing. In addition, after increasing the tumor-to-normal 




MD, mutation detected; MND, mutation not detected. 
N/A, FFPE blocks not available 
Table 21. Re-analysis of eight of eleven discordant samples in Group 3. Eight of eleven discordant samples were verified by Sanger sequencing. 
In addition, after increasing the tumor-to-normal tissue ratio, detection of EGFR mutations was re-analyzed using the cobas EGFR and ddEGFR 
tests. After enrichment of tumor tissue, the cobas EGFR test could identify previously undetected EGFR mutations in four out of the eight samples. 
However, the ddEGFR analysis yielded data identical to the preliminary results.









DIN cobas ddEGFR 
ddEGFR 
MI(%) 
Sanger cobas ddEGFR 
ddEGFR 
MI (%) 
1 11 23 3.2 MND - MD L858R 0.8 WT N/A N/A N/A N/A - 
2 11 51 2.2 MND - MD T790M/G719X 1.08 / 1.02 Invalid MND - Invalid - - 
3 6 41 4.6 MND - MD L858R 1.57 WT MD L858R MD L858R 2.57 
4 6 28 3.7 MND - MD G719X 10.17 WT MD G719X MD G719X 20.17 
5 6 12 3.9 MND - MD L858R 5.91 WT MD L858R MD L858R 4.55 
6 6 15 3.1 MND - MD L858R 7.4 WT N/A N/A N/A N/A - 
7 3 43 4.4 MND - MD 20Ins 12.88 WT MND - MD E20Ins 7.4 
8 3 34 4.1 MND - MD 19del 15.72 WT MD 19del MD 19del 3.15 
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7. Retrospective comparative clinical study for clinical utility of iQC index 
 
Next, we analyzed the EGFR mutation status of 228 samples using the ddEGFR and cobas 
EGFR tests; 57 samples were excluded based on the iQC index (Fig. 8). The remaining 171 
samples with iQC index ≥ 0.5 gave PPA of 98.23%, NPA of 82.76%, and OPA of 92.98% 
between the ddEGFR and cobas EGFR tests (κ = 0.9029, Table. 22, Table. 23). Among 12 
discordant samples, six were reported to have a double mutation according to the ddEGFR test 
but only a single mutation according to the cobas EGFR test. As expected, the MI of the 
additional detected mutation was very low. One discordant case was a mutation not detected 
by the cobas EGFR test, but detected (L861Q) by both ddEGFR test and Sanger. Conversely, 
another discordant case was a mutation not detected by the ddEGFR test but detected (19del) 
by the cobas EGFR test and Sanger (Table. 24). This was a rare mutation of the 19del subtype 
(c.2239_2264del_insGCGAA) caused by a non-specific reaction that is not designed in the 
cobas EGFR test, and thus it cannot be employed to discriminate the possibility potential 




Retrospective comparison study, 
Applied iQC index (n = 171) 
cobas EGFR Test 
MD MND Total 
ddEGFR 
Test 
MD 111  10 * 121 
MND 2 48 50 
Total 113 58 171 
 
PPA (95% C.I.) 98.23% (93.75−99.78%) 
NPA (95% C.I.) 82.76% (70.57−91.41%) 
OPA (95% C.I.) 92.98% (88.06−96.32%) 
PPV (95% C.I.) 91.74% (85.33−95.97%) 
NPV (95% C.I.) 96.00% (86.29−99.51%) 
 
* 3 samples: Cobas, 19del; ddEGFR, 19del/T790M 
   1 sample: Cobas, G719X; ddEGFR, G719X/L861Q 
   1 sample: Cobas, L858R; ddEGFR, G719X/L858R 
   1 sample: Cobas, L858R; ddEGFR, T790M/L858R 
 
Table 22. Method correlation between ddEGFR and cobas EGFR test in Retrospective 
comparison study group. Samples with valid ddEGFR and cobas EGFR test results were 
included in the agreement analysis. PPA, NPA, and OPA between the ddEGFR and cobas EGFR 
tests for the detection of EGFR mutations were 98.23%, 82.76%, and 92.98%, respectively. 





Applied iQC index 
(n = 171) 
cobas EGFR Test 














G719X 2             2 
19del  46            46 
T790M   0           0 
E20Ins    2         1 3 
S768I     0         0 
L858R      54       2 56 
L861Q       0      1 1 
19del,T790M  3      1      4 
G719X,S768I         3     3 
G719X,L858R      1    0    1 
G719X,L861Q 1          0   1 
T790M,L858R      1      3  4 
N/A  2           48 50 
Total 3 51 0 2 0 56 0 1 3 0 0 3 52 171 
 
ĸ coefficient = 0.9029 (95% C.I. 85.08−95.49%) 






cobas EGFR test ddEGFR test ddEGFR MI Sanger Seq 
1 MND - MD L858R L858R, 25.47% Invalid 
2 MD L858R MD L858R/T790M L858R, 42.9% T790M, 1.01% L858R 
3 MD 19del MD 19del/T790M 19del, 12.79% T790M, 0.96% 19del 
4 MD L858R MD L858R/G719X L858R, 43.22% G719X, 1.98% Invalid 
5 MD 19del MD 19del/T790M 19del, 22.45% T790M, 1.22% 19del 
6 MD 19del MD 19del/T790M 19del, 47.94% T790M, 0.87% 19del 
7 MD 19del MND - - WT 
8 MND - MD E20Ins E20Ins, 14.55% Invalid 
9 MD 19del MND - -   19del * 
10 MND - MD L861Q L861Q, 64.93% L861Q 
11 MD G719X MD G719X/L861Q G719X, 11.36% L861Q, 13.64% Invalid 
12 MND - MD L858R L858R, 6.46% Invalid 
* This was a rare mutation of the 19del subtype (c.2239_2264del_insGCGAA) caused by a non-specific reaction that is not designed in the cobas 
EGFR test, and thus it cannot be employed to discriminate the possibility potential erroneous detection (129). 
Table 24. Discordant analysis by Sanger sequencing in the retrospective comparison study group. Based on the results of the retrospective 
comparison with cobas EGFR test, 12 samples were valid and discordant with the ddEGFR test. Samples that gave discordant results between the 
cobas EGFR and ddEGFR tests were analyzed by Sanger sequencing. MD, mutation detected; MND, mutation not detected. 
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In addition, we measured DIN values from 228 FFPET-DNA samples and observed a pattern 
similar to that of iQC index. Furthermore, the majority of the most recent samples (within 1 
year) had DIN > 2.5 and iQC index ≥ 0.5 (Fig. 18). These data revealed that iQC index is a 
very powerful indicator of the quality of FFPET-DNA. In addition, these observations 
demonstrate that the ddEGFR test is a robust diagnostic tool for the accurate detection of EGFR 






Figure 18. Distributions of iQC index and DIN in the retrospective comparative study 
group. Most of the more recent samples (taken within 1 year) satisfied the sample criteria 














FFPETs undergo effective preservation of the cellular, architectural, and morphological 
details and allow easy storage at room temperature for extensive periods. For these reasons, 
FFPET is useful source for molecular diagnostics. But, the quality of FFPET-DNA has been 
largely ignored in the clinical research and diagnosis field, and internal control of most 
commercial diagnostic kits were used only to validate assays. Changes in mutation status due 
to the low quality of FFPET-DNA may result in incorrect diagnoses. Therefore, considerable 
effort is required to optimize the sample criteria for determining the quality of FFPET-DNA 
that is suitable for PCR. In this study, we established iQC index criteria to determine the 
minimum quality of FFPET-DNA and demonstrated the benefits of implementing these criteria 
benefits in a real-world clinical application. 
In our experiments, both automated tissue preparation system (TPS; Siemens Healthcare, 
Erlangen, Germany), which can minimize handling errors and decrease the effect of 
formaldehyde-induced DNA–DNA and DNA–protein crosslinks (51, 58), and UDG treatment 
are powerful strategy for reducing false positives caused by sequence artifacts (61, 130-132). 
However, sequence artifacts due to DNA fragmentation remained a problem. Limitations in the 
availability of many clinical specimens drive the need for low DNA inputs into molecular 
assays. Cutting edge technologies such as NGS required good quality of DNA material for in-
depth molecular profiling in various cancer (133). None of traditional tools such as UV 
absorbance, gel electrophoresis, assays with intercalating dyes measure the amount of 
amplifiable DNA, and each of these tools has an additional limitations (134). Also, depending 
on the degree of fragmentation, the same quantities of DNA from different FFPET samples can 
contain widely different amounts of amplifiable DNA templates (59). For this reason, PCR-
based methods such as qPCR, ddPCR, and next-generation sequencing (NGS) are preferable 
for quantifying the amount of amplifiable template in FFPET-DNA (119).  
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iQC copies can represent the concentration of input DNA (Fig. 11, 12) and a novel concept 
for mutation calling, MI, was introduced as an indicator of the mutation level, which in turn 
reflects DNA quality. MI provides a much more accurate indication of the mutation level than 
mutation frequency, which is simply calculated based on input DNA concentration. 
Accordingly, we designed an iQC that measures EGFR exon 20 to assess the amount of 
amplifiable FFPET-DNA. Because elevated EGFR expression have been observed in NSCLC 
(128), the internal control should be designed to represent the levels of the EGFR gene copy 
number.  
Interestingly, some discordant samples reported as single mutations by the cobas EGFR test 
were shown to have double mutation by the ddEGFR test in pre-clinical (Table. 17) and clinical 
studies (Table. 22). The additional detected MI was around 1%, as expected. According to a 
clonal selection model, EGFR-TKI treatment may lead to the selection of T790M mutant cells, 
and thus even a small fraction of T790M positive tumor cells at the beginning of treatment 
could lead to clinical EGFR-TKI resistance (25). Therefore, is very important to detect even a 
small fraction of mutations.  
The discordant results were largely due to the difference in LoD between both tests. 
Specifically, some mutations detected by the ddEGFR test cannot be detected by the cobas 
EGFR test because the sensitivity of the ddEGFR test is higher. In the pre-clinical study Group 
3, L858R MIs were relatively low in cobas EGFR-negative samples (around 5%, Table. 21). 
Considering that the LoD of the cobas EGFR test was 5%, these MI values, which reflect 
sample quality and mutation level, are reasonable. When the iQC index was applied, the 
proportion of such discordant samples was small. 
The cobas EGFR test recommends macrodissection of low-percent tumor tissues (below 
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10%) to improve detectability (126). When the cobas EGFR test yielded a result of ‘mutation 
not detected’ (MND), even though the C/N ratio was over 10%, the EGFR mutation was re-
analyzed after increasing the tumor ratio by macrodissection. The cobas EGFR test yielded the 
same results as the ddEGFR test for four of the eight samples (Table. 21), showing that ddEGFR 
exhibits superior analytical performance. Thus, the detectability of the cobas EGFR test may 
be increased by enriching for tumor tissue, e.g., by macrodissection, but this manipulation 
requires extra time and effort. By contrast, the ddEGFR test does not require macrodissection 
and improves reliability. 
For 1-year-old samples (n = 46) in the clinical study group, all iQC index and DIN values 
satisfied the sample criteria (iQC index ≥ 0.5, DIN > 2.5) (Fig. 18), suggesting that the low age 
samples used in clinical practice will have minimal problems with DNA quality. Previous 
reported that, cobas EGFR test and Sanger are highly concordant because used to low age 
samples (50, 135, 136). In contrast, concordance rate between cobas EGFR test and Sanger of 
the pre-clinical study samples were very low (Table. 10, Table. 11), but when iQC index was 
applied, the concordance rate was increased (Data not shown). Given the additional cost and 
effort required for DIN measurement, the iQC index is a robust indicator of the minimum DNA 
quality required for PCR amplification, as it takes into account the various types of DNA 
damage caused by FFPET processing and long-term storage.  
In addition, iQC index ≥ 0.5 is an indicator that guarantees clinical equivalence obtained 
through comparative clinical studies with existing approved diagnostics test (cobas EGFR test). 
Clinical equivalence cannot be guaranteed for samples with an iQC index < 0.5. However, 
discordance of samples with iQC index < 0.5 can be explained by two causes. The first cause 
may be due to the possibility of false negative results of cobas EGFR test. Second, there is a 
possibility of false positive result due to ultra-sensitivity of ddEGFR test. The analytical 
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performance of the ddEGFR test indicates a high possibility of false negative results on the 
cobas EGFR test. However, it is questionable whether mutations detected in samples with an 
iQC index < 0.5 (especially mutations detected at low MI %) are related to drug treatment 
response. This must be verified through prospective clinical trials. Small-scale independent 
retrospective clinical studies for the ddEGFR test have shown responses of patients treated with 
an EGFR-TKI, even of patients with an iQC index < 0.5 (unpublished). Therefore, an iQC 
index ≥ 0.5 is a numerical value used in comparative clinical studies to guarantee clinical 
equivalence between the results of the ddEGFR and cobas EGFR tests. This means that iQC 
index may be changed through an independent prospective clinical trial for ddEGFR test. Also, 
using another approved kit for comparative clinical study, the iQC index may be changed for 
clinical equivalence. This is the result of considering clinical cut-off not only to compare the 
mutation results but also to ensure EGFR-TKI response. 
We also observed that the iQC index could be used to obtain a diagnosis using other cancer 
type samples (colorectal cancer) and other diagnostic kits, including the ddPCR-based KRAS 
mutation test and the cobas®  KRAS mutation test. Similar to the results of this study, we 
observed that when the iQC index was applied, the concordance rate between the results of the 
two kits increased significantly (data not shown). Overall, the iQC index could be a useful 
criterion for judging the quality of FFPET-DNA. 
The ddEGFR test is designed to detect the C797S mutation in EGFR exon 20. NSCLC 
patients with advanced disease are usually treated with first or second generation EGFR-TKIs 
(erlotinib, gefitinib, or afatinib) (137, 138). However, patients acquire resistance after 9 to 13 
months (34, 139, 140), the most common being T790M within the EGFR kinase domain (22, 
24). Third generation EGFR-TKI have been designed to mutant-selectively target highly active 
against T790M mutation (141, 142). Recently, ctDNA evaluation was used to identify a novel 
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mechanism underlying acquired resistance to the third generation EGFR-TKI osimertinib; 
specifically, emergence of an acquired EGFR C797S mutation (33). The pre-clinical and 
retrospective clinical studies based on the ddEGFR test did not detect the C797S mutation. 
However, we subsequently found out that none of the NSCLC patients in those studies actually 
received a third generation EGFR-TKI. 
Diagnostic kits must be able to detect mutations in very small amounts of DNA with high 
sensitivity. One of the problems associated with detecting EGFR mutations in NSCLC patients 
is not obtaining a sufficient quantity of specimen to confirm the status of several biomarkers. 
The ddEGFR test can detect EGFR mutations using only 3.3 ng (total 13.2 ng/4 wells) of 
FFPET-DNA per well, with a sensitivity of 0.78%. With cobas EGFR test, 3 reactions were 
performed using 50 ng DNA per well (total 150 ng / 3 well) to detect 42 EGFR mutations.  
The presence of EGFR mutations in NSCLC is a major prognostic biomarker in terms of 
treatment selection. Thus, sensitive and accurate screening for EGFR mutations facilitates a 
personalized and specific approach to patient treatment / management.  
In conclusion, detecting genetic mutations in FFPET samples is difficult because the DNA 
often becomes fragmented during storage, resulting in sequence artifacts and low-quality data. 
The iQC index allows selection of appropriate FFPET-DNA samples for companion 
diagnostics using a ddPCR-based mutation test. Furthermore, we suggest that clinical trials 
using FFPET should involve criteria that reflect the quality of the DNA in samples. The 
performance of the ddPCR-based EGFR mutation test developed herein was superior to that of 


















Personalized treatment for cancer patients should include a genetic assessment of mutation 
status. FFPET is the most widely available material for molecular diagnostics and research. 
FFPET samples are routinely used for histopathological analysis because they are convenient, 
cost-effective, and easy to store. However, detecting genetic mutations in FFPET samples is 
difficult because DNA fragments during storage, resulting in sequence artifacts. DNA 
fragmentation is an irreversible reaction that not only reduces the amount of amplifiable 
template but also leads to stochastic enrichment of artifactual changes. However, since 
mutational analyses of FFPETs is a standard procedure used to inform therapeutic decisions, 
appropriate measures must be incorporated to allow assessment of DNA damage and prevent 
the calling of false-positive mutations.  
For reliable analysis of mutations, it is necessary to pre-analyze and evaluate the 
amount/quality of amplifiable template FFPE DNA. The more sensitive test method, the higher 
purity DNA is required. Traditional quantitation methods such as UV absorbance and 
spectrophotometry lack accuracy when it comes to measuring the amount of amplifiable 
template DNA. Evaluating the amount of amplifiable DNA is very important in diagnosis using 
PCR-based methods. Up to this time, the PCR-based diagnostic test reflected only the validity 
and invalidity of the assay, not considering the quality of the DNA. The iQC index established 
herein enables accurate detection of EGFR mutations. If using PCR-based assays to detect 
EGFR mutations, we believe that the results can be trusted if at least half of the input DNA is 
amplifiable. The iQC index allows appropriate selection of FFPET DNA samples for 
companion diagnosis using a ddPCR-based mutation test. In addition, DNA quality and EGFR 
mutations are analyzed simultaneously in same NSCLC FFPET sample. The results are reliable, 
even though only a small amount of FFPET DNA is required. Indeed, we found that the 
analytical performance of the ddPCR-based EGFR mutation test was superior to that of the 
89 
 
Cobas EGFR test. Measuring the quality of DNA extracted from patient samples makes it 
possible to prevent diagnostic errors, allow re-testing where appropriate, and make decisions 
regarding appropriate treatment (Fig. 19). The results of this study will also be of benefit to 
clinical researchers. As mentioned above, handling and storage procedures vary from site to 
site, and multi-center clinical trials that do not take sample quality into account can yield 
unreliable results; both of these problems can be overcomed by application of the iQC index 
and standardization of sample quality (Fig. 20). 
The iQC index seems to be most useful for diagnoses based on liquid biopsy samples (e.g., 
ctDNA). The iQC index may be necessary for liquid biopsy specimens since the quality of 
ctDNA can vary diversely by frequent fragmentation, which is a biological property of ctDNA, 
variations in sample collection and storage by each hospital, and by logistic issues.  
We are currently conducting prospective clinical studies to confirm the clinical utility of the 
ddPCR-based EGFR mutation test for liquid biopsy samples. A ddEGFR test based on plasma 
samples may be both feasible and effective for identifying EGFR mutations, predicting 
treatment responses, and monitoring acquired resistance during EGFR-TKI treatment. T790M 
is the most common mutation associated with acquired resistance to first-generation EGFR-
TKIs (23). T790M is present in a small population of tumor cells during development of 
NSCLC; therefore, it may be detected at very low frequency (25). A very low level T790M not 
detected by Cobas EGFR can be sensitively detected with ddEGFR test. However, it is very 
difficult to verify using the gold standard method such as Sanger sequencing due to technical 
limitations (low sensitivity). Therefore, we intend to undertake a prospective clinical trial to 
examine the usefulness of the ddEGFR test for monitoring the activity of EGFR-TKIs in 
NSCLC patients harboring T790M at low frequency; this will inform us as to whether the test 
can predict patients that will benefit from treatment with third generation EGFR-TKIs. 
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In the near future, mutation detection tests will play a very important role in the clinical 
setting as they will identify biomarkers for molecular targeted therapy. The benefits of 
treatment will be maximized only if accurate companion diagnostics are used; these diagnostics 
must be validated according to strict standards. The ddEGFR test not only detects EGFR 
mutations but also provides information about the quality of DNA, thereby preventing 
diagnostics errors. It also offers the opportunity to decide when to appropriate treatment 














Figure 20. Clinical meaning of iQC index (viewpoint of multi-center clinical and 
translational research). Since conditions for processing and storage of samples from each 









Figure 21. Dynamic monitoring of ctDNA in NSCLC. ddPCR-based mutation test can be 
used for the quantification of dynamic changes in the EGFR, c-Met mutations in ctDNA, and 
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DNA의 특질 분석을 이용한 드롭렛 디지털 PCR 기반의  
EGFR 돌연변이 검출 방법 연구 
 
서울대학교 대학원 
약학과 병태생리학 전공 
김 성수 
 
포르말린 고정 파라핀 내장 조직 (formalin-fixed paraffin-embedded tissue, FFPET) 
샘플은 임상 연구와 체외 진단분야에 있어서 매우 중요한 자원이다. 하지만, 포르
말린 고정 파라핀 내장 조직 샘플을 이용한 유전자 돌연변이 검출은 포르말린 고
정 파라핀 내장 조직의 처리 과정 및 다양한 보존기간과 품질로부터 기인하는 문
제점으로 인하여 부정확한 결과를 초래한다.  
본 연구는 315 개의 비소세포 폐암 환자의 FFPET-DNA 샘플을 사용한 전임
상 연구를 통하여 ddPCR 기반 (GenesWell™ ddEGFR Mutation test, “ddEGFR test”)과 
Real-time PCR 기반의 EGFR 돌연변이 테스트 (cobas®  EGFR Mutation test, “cobas 
EGFR test”) 를 비교함으로써 PCR에 적합한 최소 DNA 품질을 반영하는 샘플 기
준을 확립했다. 확립된 샘플 기준을 사용하여 171개의 비소세포 폐암 환자의 
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FFPET-DNA 샘플을 사용한 독립된 후향적 임상 연구에서 ddEGFR 및 cobas EGFR 
test에 대한 비교 임상 및 샘플 기준의 임상적 유용성을 평가 하였다.  
전임상 연구를 통하여 FFPET-DNA의 샘플 기준 (iQC index ≥ 0.5, iQC copies 500 
이상, FFPET-DNA가 3.3 ng [1000 GE]을 사용)을 확립 하였고, 이는 Input DNA 농도
를 기준으로 절반 이상이 증폭 가능함을 의미한다. iQC index를 적용한 전임상 샘
플 150개를 재 분석 하였고, ddEGFR test와 Cobas EGFR test의 일치율이 92.67%로 
증가 하였다 (전임상 샘플 315개 전체 일치율 = 78.10%). iQC index를 기반으로, 독
립적인 후향적 임상 시험을 실시 하였고, ddEGFR test와 Cobas EGFR test의 일치율
이 매우 높게 관찰 되었다 (OPA = 92.98%). 또한, cobas EGFR test에서 검출하지 못
하는 샘플들을 ddEGFR test를 사용하여 민감하게 검출 하였다. 
iQC index는 FFPET-DNA 의 품질을 반영하는 신뢰할 수 있는 지표이며 매우 
낮은 품질의 샘플로부터 기인하는 부정확한 진단을 방지할 수 있다. 또한, 기 
허가 받은 cobas EGFR test와 비교하여, ddEGFR test는 우수한 분석적 성능 및 
적어도 동등한 임상적 성능을 나타냈다.  
 
주요어: 상피세포성장수용체; 포르말린 고정 파라핀 내장 조직; 핵산 무결성 지수; 
드롭렛 디지털 중합효소 연쇄반응; 유전자 돌연변이 검출; 핵산 내부 품질 지수 
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